Aripiprazole
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Aripiprazole: From Schizophrenia and Bipolar Disorder to Major Affective Disorder
One-Sentence Summary
Aripiprazole is an atypical antipsychotic originally approved for schizophrenia and bipolar I disorder, acting as a partial agonist at dopamine D2/D3 and serotonin 5-HT1A receptors. The TxGNN model predicts it may be effective for Major Affective Disorder, with 50 clinical trials and 20 publications currently supporting this direction. The evidence base is particularly strong: multiple completed Phase 3 RCTs and several systematic reviews and meta-analyses confirm aripiprazole’s efficacy as an adjunctive treatment for major depressive disorder, consistent with its existing FDA approval in this setting.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No MHRA licence data available in this dataset; aripiprazole is established for schizophrenia and bipolar I disorder in other jurisdictions |
| Predicted New Indication | Major Affective Disorder |
| TxGNN Prediction Score | 99.62% |
| Evidence Level | L1 |
| UK Market Status | Not currently marketed (no MHRA licences recorded in this dataset) |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Aripiprazole has a distinctive mechanism of action that sets it apart from earlier antipsychotics. It acts as a partial agonist at dopamine D2 and D3 receptors and at serotonin 5-HT1A receptors, whilst simultaneously functioning as an antagonist at 5-HT2A receptors. This dual modulation of the dopamine and serotonin systems — stabilising rather than fully blocking or activating them — gives aripiprazole a unique pharmacological profile sometimes described as a “dopamine–serotonin system stabiliser.”
Major affective disorder encompasses both major depressive disorder (MDD) and bipolar affective disorder, conditions characterised by disruption of monoaminergic neurotransmission in the prefrontal cortex, limbic system, and striatum. The dopaminergic hypothesis of depression holds that insufficient dopamine tone in the mesocortical pathway contributes to anhedonia and cognitive symptoms, whilst abnormal mesolimbic signalling underlies mood cycling in bipolar disorder. Aripiprazole’s partial D2 agonism can correct this imbalance — acting as a functional agonist when dopamine tone is low and as a functional antagonist when it is excessive. Its 5-HT1A partial agonism may additionally contribute anxiolytic and antidepressant effects via serotonergic feedback circuits.
The clinical evidence strongly supports this mechanistic reasoning. The US FDA has already granted aripiprazole an approved indication as an adjunctive therapy for MDD (in combination with SSRIs or SNRIs), and separately for acute and maintenance treatment of bipolar I disorder. Multiple Phase 3 RCTs — including a pivotal 586-patient double-blind placebo-controlled trial (NCT00876343) and a 1,200-patient multi-centre study (NCT00095823) — have confirmed its efficacy in MDD augmentation. The TxGNN prediction score of 99.62% is therefore mechanistically coherent and strongly supported by existing clinical evidence.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT00876343 | Phase 3 | Completed | 586 | Double-blind, placebo-controlled RCT of aripiprazole vs placebo as adjunctive therapy with SSRI/SNRI in MDD — core Phase 3 efficacy and safety evidence for MDD augmentation |
| NCT00095823 | Phase 3 | Completed | 1,200 | 14-week multi-centre RCT of aripiprazole as adjunctive treatment to ongoing antidepressant therapy in MDD |
| NCT02046564 | Phase 3 | Completed | 412 | Fixed-dose ASC-01 (aripiprazole/sertraline combination) vs sertraline monotherapy in MDD with incomplete response to sertraline |
| NCT00107939 | Phase 3 | Completed | 453 | Licarbazepine adjunctive to atypical antipsychotics (including aripiprazole) for bipolar I manic episodes; confirms aripiprazole’s role as an active comparator in bipolar mania |
| NCT02305823 | Phase 4 | Completed | 203 | Head-to-head comparison of aripiprazole vs quetiapine vs ziprasidone in first-episode non-affective psychosis (PAFIP II); provides real-world effectiveness and tolerability data |
| NCT00683852 | Phase 3 | Completed | 225 | Double-blind, placebo-controlled study of reduced-dose aripiprazole as adjunctive therapy in MDD patients with inadequate response to prior antidepressant treatment |
| NCT00882362 | Phase 3 | Completed | 155 | Long-term safety and efficacy of aripiprazole as adjunctive therapy with SSRI/SNRI in MDD; companion study to NCT00876343 |
| NCT03423680 | Phase 3 | Recruiting | 390 | 8-week RCT of aripiprazole adjunctive to mood stabiliser for major depressive episode in bipolar I or II disorder; expected completion December 2025 |
| NCT01111565 | Phase 3 | Terminated | 137 | Aripiprazole/escitalopram oral combination in MDD with incomplete escitalopram response; terminated early limiting statistical power, but provides safety signal data |
| NCT00667745 | Phase 4 | Completed | 283 | LiTMUS: Randomised effectiveness trial of lithium as part of optimised treatment in bipolar disorder — contextual evidence for broader affective disorder pharmacotherapy |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 38669232 | 2024 | Systematic Review / Meta-Analysis | PLoS ONE | First large-scale meta-analysis of RCTs comparing aripiprazole augmentation and switching in TRD/MDD; demonstrates favourable efficacy with acceptable tolerability profile |
| 34986373 | 2022 | Systematic Review / NMA | J Affect Disord | Network meta-analysis comparing augmentation agents for treatment-resistant depression; aripiprazole among the most extensively studied and efficacious agents |
| 38219278 | 2024 | Systematic Review / NMA | Neuropsychopharmacol Rep | NMA comparing brexpiprazole vs aripiprazole vs placebo for Japanese patients with MDD; supports aripiprazole efficacy as an augmentation strategy in this population |
| 35510505 | 2023 | Systematic Review / Meta-Analysis | Psychol Med | Comprehensive meta-analysis of antipsychotic monotherapy and adjunctive therapy in MDD across multiple agents; confirms aripiprazole efficacy in both modes |
| 34167174 | 2021 | Systematic Review / Meta-Analysis | Prim Care Companion CNS Disord | Long-term (≥6 months) efficacy and tolerability of adjunctive aripiprazole for MDD; remission rate and adverse event profile systematically assessed |
| 37746943 | 2023 | Systematic Review / NMA | Medicine | NMA comparing 4 atypical antipsychotics as augmentation agents in MDD; provides comparative efficacy and safety rankings including aripiprazole |
| 37149344 | 2023 | Narrative Review | Psychiatr Clin North Am | Pharmacotherapy for treatment-resistant depression: aripiprazole identified as the most widely studied augmentation agent among atypical antipsychotics |
| 25963405 | 2016 | Review | Asia-Pac Psychiatry | Antipsychotics as antidepressants: aripiprazole noted among three SGAs with FDA approval for adjunctive treatment of MDD; mechanistic receptor-profile analysis |
| 36855876 | 2023 | Review | Am J Psychiatry | Antipsychotics in the evolving TRD therapeutic landscape; positioning of aripiprazole alongside newer agents brexpiprazole and cariprazine |
| 37815563 | 2023 | Narrative Review | JAMA | JAMA overview of diagnosis and treatment of bipolar disorder, encompassing pharmacological strategies including atypical antipsychotics |
UK Market Information
No MHRA marketing authorisation records for aripiprazole are available in this evidence pack (total licences recorded: 0; market status: not currently marketed in this dataset).
Note for clinicians: Aripiprazole (brand name Abilify) holds marketing authorisations in multiple jurisdictions including the USA and EU. Clinicians should verify the current authorisation status directly via the MHRA Product Licence Search and consult the current BNF (British National Formulary) entry before prescribing. Any relevant NICE Technology Appraisals or Clinical Guidelines covering aripiprazole in mood disorders should also be reviewed.
Safety Considerations
Specific warnings, contraindications, and drug–drug interaction records are not available in this evidence pack.
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Multiple completed Phase 3 RCTs (NCT00876343, n=586; NCT00095823, n=1,200; NCT02046564, n=412) alongside multiple systematic reviews and meta-analyses provide robust Level 1 evidence confirming the efficacy and tolerability of aripiprazole as an adjunctive treatment for major depressive disorder; the FDA’s existing approval in this setting provides a strong regulatory precedent for MHRA consideration.
To proceed, the following is needed:
- Obtain and review the current MHRA-approved SmPC (or initiate the appropriate UK regulatory pathway) to confirm UK-specific dosing, contraindications, and warnings
- Verify current UK marketing authorisation status via the MHRA Product Licence Search and identify any applicable NICE guidance or clinical guidelines
- Conduct a formal drug–drug interaction assessment, particularly for combinations with SSRIs and SNRIs (CYP2D6 and CYP3A4 interactions are clinically relevant)
- Establish a safety monitoring plan covering extrapyramidal symptoms (including akathisia), body weight and metabolic parameters, impulse control disorders (compulsive gambling and hypersexuality are recognised adverse effects), and QTc monitoring where indicated
- Apply the class warning regarding increased all-cause mortality in elderly patients with dementia-related psychosis before any use in this population
- Confirm the prescribing pathway (licensed versus off-label) and ensure appropriate clinical governance and patient consent frameworks are in place
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.